Weight Drug Suits Highlight Need For Legal Work On Safety
The rapid ascent of glucagon-like peptide-1 receptor agonists, or GLP-1 RAs — such as Novo Nordisk's Ozempic and Wegovy, and Eli Lilly & Co.'s Mounjaro and Zepbound — has revolutionized diabetes...To view the full article, register now.
Already a subscriber? Click here to view full article